Marvel Biosciences Corp. (MRVL.V)
| Previous Close | 0.0900 |
| Open | 0.1000 |
| Bid | 0.0900 x N/A |
| Ask | 0.0950 x N/A |
| Day's Range | 0.0950 - 0.1000 |
| 52 Week Range | 0.0750 - 0.1700 |
| Volume | |
| Avg. Volume | 16,284 |
| Market Cap | 3.78M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Newsfile
Marvel Commences Final Study Required Prior to Initiating Human Trials
Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204."This dog study is the last of the two key primary animal studies we need to complete before entering phase ...
- Newsfile
Marvel Biosciences Initiates Four Week Rat GLP Toxicology Study
Calgary, Alberta--(Newsfile Corp. - March 9, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging rat studies for its lead drug candidate MB-204."This rat study, along with the GLP study on dogs, are the last two key studies we need to complete ...
- Newsfile
Marvel Biosciences Announces Closing of First Tranche of Debenture Offering
Calgary, Alberta--(Newsfile Corp. - February 24, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) ("Marvel" or the "Corporation") announced today that it has completed the closing of the first tranche of the previously announced non-brokered private placement of debentures ("Debentures") for gross proceeds of $1,000,000 (the "Private Placement"), subject to final approval of the TSX Venture Exchange.The Debentures bear interest at the rate of eight percent (8%) per annum, payable annually and matur
